Back to Search Start Over

BioBanking as the central tool for translational medicine CTM issue 2013

Authors :
György Marko‐Varga
Source :
Clinical and Translational Medicine, Vol 2, Iss 1, Pp n/a-n/a (2013)
Publication Year :
2013
Publisher :
Wiley, 2013.

Abstract

Abstract The impact of mapping the human proteome: Globally, the health care organizations are under resource and cost constrains due to the increasing number of patients that are due to a fast increase of the 65+ age group requiring extensive medical hospitalization and treatments. Hospitals worldwide strive to seek the best cure for patients, suffering from various diseases. A consequence of these global changes, of healthy populations in relation to patients forms the basis for the build of large and centralized biobank facilities, with strategies where the search for an understanding of diseases at a molecular level is at heart. The efforts made lies within large governmental resource allocations where patient centers are collecting samples from clinical study participants in order to try to discover universal expression patterns and molecular signatures of disease and disease stages. Most developments in this area are aimed towards the discovery, and understanding diagnosis implementations. By providing the right treatment alternatives for patients care, at the right time point i.e., at a given disease stage development becomes a major goal where pharmaceutical industry, academia and the health care sector joins forces in large clinical epidemiological, population‐, and disease based studies. This becomes a clear strategic link to the enhancement and prospects for personalized medicines and target directed diagnosis developments (Companion Diagnostics), which require coordinated efforts across a wide range of disciplines. Currently, companion diagnostics is at the core of the personalized medicine paradigm shift. It will identify patients who are most likely to benefit from a particular therapeutic product, as well as identify patients likely to be at increased risk for serious adverse reactions as a result of treatment with a particular therapeutic agent. It is predicted that more than half of all new drugs will require a companion diagnostic, which opens up for an endeavor for Proteomics research implementations.

Subjects

Subjects :
Medicine (General)
R5-920

Details

Language :
English
ISSN :
20011326
Volume :
2
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Clinical and Translational Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.5c4a76cc7701479b8eb5cf0821351e1b
Document Type :
article
Full Text :
https://doi.org/10.1186/2001-1326-2-4